US 12,006,283 B2
HIF-1α inhibitor, preparation method therefor, and pharmaceutical composition for preventing or treating angiogenesis-associated eye disease, containing same as active ingredient
Youngger Suh, Seoul (KR); Seungbeom Lee, Seoul (KR); and Jeonghun Kim, Seoul (KR)
Assigned to SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION, Seoul (KR)
Appl. No. 17/057,297
Filed by SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION, Seoul (KR)
PCT Filed Aug. 12, 2019, PCT No. PCT/KR2019/010208
§ 371(c)(1), (2) Date Nov. 20, 2020,
PCT Pub. No. WO2020/045856, PCT Pub. Date Mar. 5, 2020.
Claims priority of application No. 10-2018-0103985 (KR), filed on Aug. 31, 2018; and application No. 10-2019-0096669 (KR), filed on Aug. 8, 2019.
Prior Publication US 2021/0188753 A1, Jun. 24, 2021
Int. Cl. C07C 49/84 (2006.01); C07C 225/22 (2006.01); C07C 255/59 (2006.01); C07D 207/08 (2006.01); C07D 211/22 (2006.01); C07D 265/30 (2006.01)
CPC C07C 49/84 (2013.01) [C07C 225/22 (2013.01); C07C 255/59 (2013.01); C07D 207/08 (2013.01); C07D 211/22 (2013.01); C07D 265/30 (2013.01)] 5 Claims
 
1. A compound represented by the following Formula (1), or a solvate, hydrate, optical isomer or pharmaceutically acceptable salt thereof:

OG Complex Work Unit Chemistry
A1 and A2 are methoxy or A1 is H and A2 is F;
B1 is —H, or C1-10 straight- or branched-chain alkoxy; and
R1 is C3-10 cycloalkyloxy, heterocycloalkyl of a 5- to 10-membered ring containing at least one heteroatom selected from the group consisting of N, O and S, or benzylamino unsubstituted or substituted with —CN.